Tag: 106190

1. What Happened? – Analysis of Hitech Pharm’s Shareholding Change Disclosure

On September 22, 2025, ACS Dobfar S.p.A. (Italy), a major shareholder of Hitech Pharm, disclosed a ‘Report on the Status of Large Shareholdings.’ The key takeaway is a slight decrease in ACS Dobfar’s stake from 47.50% to 47.04% due to changes in special relationships and shareholdings. The specific reason is a change in shareholdings due to Mr. Park Jin-yong’s market purchase.

2. Why Does It Matter? – The Significance of the Shareholding Change and Fundamental Analysis

While this change doesn’t signify a shift in management control, it’s noteworthy as it reflects the actions of a major shareholder. This is particularly relevant given Hitech Pharm’s current challenge of declining capacity utilization rates, as the change could influence investor sentiment. Solid performance, a stable export-oriented business structure, and continued R&D investment are positive factors, but exchange rate volatility and inventory management pose risks.

3. What Should You Do? – Future Stock Price Outlook and Investment Strategy

While this shareholding change itself is not expected to significantly impact the stock price, investors should monitor the future actions of major shareholders and the company’s fundamental improvements. Key variables that will influence the future stock price include improvements in capacity utilization rates, additional shareholding changes by major shareholders, and the company’s exchange rate hedging strategy.

4. Investor Action Plan

• Short-term investors: Be aware of the potential for increased short-term stock price volatility. A wait-and-see approach is recommended rather than chasing the stock.
• Mid-to-long-term investors: Continuously monitor Hitech Pharm’s fundamental improvement and changes in major shareholder stakes. Develop an investment strategy from a long-term perspective.